12th Congress of the European Hematology ... - Haematologica

More documents

Recommendations

Info

12 th Congress of the European Hematology Association advanced-stage HD patients consecutively admitted to seven Italian hematological institutions were enrolled in a prospective multicenter clinical trial to study the predictive role on treatment outcome of early interim FDG 'PET scan in HD patients treated with BEACOPP (4 escalated + 4 baseline cycles). Patients The mean age was 35,3 years (18-60); advanced disease (stages IIB-IVB) was present in 26, and stage IIA with adverse prognostic factor (> 3 nodal sites involved, sub-diaphragmatic presentation, bulky disease and ESR > 40) in 3. Bulky disease and extra nodal sites were recorded in 16 and 14 patients, respectively. All pts were staged at baseline, after 2 courses of chemotherapy at the end of treatment by FDG-PET scan (PET-0, PET-2, PET-8, respectively). All the PET-2 positive studies were reviewed. The mean interval between the end of the second BEACOPP course and PET-2 was 11.6 (5-20). At the end of chemotherapy in 15/29 pts. with bulky disease consolidation radiotherapy was given. All patients were given the therapy programmed at baseline. No treatment change depending on PET-2 result was allowed, except in case of overt progression. Results. the mean follow-up was 637 days (259-1428). Twenty-six pts attained CR while 3 were chemoresistant and showed disease progression during therapy; three patients relapsed + 55, + 224 and +266 days after CR entry. In univariate analysis, besides PET-2 (p
factor for the achievement of CR was SXR -1567T>C polymorphism (RR=0.5; p=0.06). A lower probability of DFS was associated with IL10 -116A>G polymorphism (RR=0.2; p=0.02), and a lower probability of OS to higher Hasenclever prognostic index (RR=6.4; p
Page 1 and 2:
haematologica the hematology journa
Page 3 and 4:
Information for readers, authors an
Page 5 and 6:
EHA Executive Board E. Hellström-L
Page 7 and 8:
Poster session I POSTER SESSION POS
Page 9 and 10:
12 th Congress of the European Hema
Page 11 and 12:
dasatinib. Methods. We studied Ikar
Page 13 and 14:
Expression of the oncogene H-Ras an
Page 15 and 16:
is the gene for the erythropoietin
Page 17 and 18:
safety of a slow-release liposomal
Page 19 and 20:
0029 OUTCOME OF THE TREATMENT OF AD
Page 21 and 22:
drug-induced apoptotic response of
Page 23 and 24:
41% in the PI3K- group (p=0.001). I
Page 25 and 26:
Acute myeloid leukemia - Clinical I
Page 27 and 28:
to 60 years (n=116, or 72%) receive
Page 29 and 30:
0056 PROGNOSTIC SIGNIFICANCE OF FLT
Page 31 and 32:
Anemia and Bone marrow failure 0061
Page 33 and 34:
tified with the current protocol. S
Page 35 and 36:
new cases of lead poisoning due to
Page 37 and 38:
icance, from baseline to week 6 (p
Page 39 and 40:
0086 THROMBELASTOGRAPHIC CHART RELI
Page 41 and 42:
trials. The aim of this retrospecti
Page 43 and 44:
tant function in this disease, nega
Page 45 and 46:
ed to a favorable outcome. Bialleli
Page 47 and 48:
stronger levels of p21 in the cell
Page 49 and 50:
hematological centers in one countr
Page 51 and 52:
ure 1). Conclusions. Results for re
Page 53 and 54:
patients. After a median follow-up
Page 55 and 56:
Cytogenetics and Molecular diagnost
Page 57 and 58:
0135 ROUTINE DETECTION OF CYTOGENET
Page 59 and 60:
(MMolR, defined as a BCR-ABL x 100
Page 61 and 62:
0146 ARSENIC TRIOXIDE INDUCES ACCUM
Page 63 and 64:
tinguish between genotypic B-cell l
Page 65 and 66:
Genomics and proteomics 0158 PLASMA
Page 67 and 68:
0164 EVALUATION OF MULTIPLEX LIGATI
Page 69 and 70:
each patient’s replicate conditio
Page 71 and 72:
0174 RELATION BETWEEN LOW PML-RARα
Page 73 and 74:
0179 ESHAP VS GIN AS SALVAGE AND MO
Page 75 and 76:
Immunology and gene therapy 0184 EA
Page 77 and 78:
Cell viability was not affected by
Page 79 and 80:
month is not relevant to chronic Gv
Page 81 and 82:
Infection and supportive care I 020
Page 83 and 84:
0206 POTENTIAL ROLE OF CMV IN THE O
Page 85 and 86:
3H-thymidine uptake in cell culture
Page 87 and 88:
0217 TUBERCULOSIS AMONG A COHORT OF
Page 89 and 90:
0222 COMPARISON OF IWG 2006 AND IWG
Page 91 and 92:
tem (IPSS) to h-MDS was also invest
Page 93 and 94:
PCH97-19) were studied. Conventiona
Page 95 and 96:
of erythroid colonies was reduced i
Page 97 and 98:
0245 POTENT AND SELECTIVE INHIBITIO
Page 99 and 100:
0250 INACTIVATION OF SUPPRESSOR OF
Page 101 and 102: Bortezomib 1.3 mg/m 2 days 1,4,8,11
Page 103 and 104: Response was defined according to E
Page 105 and 106: G-CSF can be used in neutropenic pa
Page 107 and 108: ence and functional activity of CD8
Page 109 and 110: itating tumor development, or engag
Page 111 and 112: phoma and SNT-13, -15 were establis
Page 113 and 114: usage (2/20 ie 10%) were observed.
Page 115 and 116: 0294 MYCOSIS FUNGOIDES. IMMUNOHYSTO
Page 117 and 118: (range, 1-6) and 11 treatment cycle
Page 119 and 120: 0306 RISK-ADAPTED IMMUNOCHEMOTHERAP
Page 121 and 122: functional activity was confirmed b
Page 123 and 124: No major toxicity, neither hematolo
Page 125 and 126: enewal potential of X-RAR-positive
Page 127 and 128: (50-99) respectively. Serial analys
Page 129 and 130: cell-interaction, adhesion and acti
Page 131 and 132: 0340 ALTERED FIBRIN CLOT STRUCTURE
Page 133 and 134: Conclusions. This study demonstrate
Page 135 and 136: 0354 FACTOR V LEIDEN HOMOZYGOUS GEN
Page 137 and 138: Results. From July 2005 through Mar
Page 139 and 140: 0364 CLINICAL EFFICACY OF OXALIPLAT
Page 141 and 142: one marrow and peripheral blood ste
Page 143 and 144: ecently suggested (Boissel et al.,
Page 145 and 146: 0378 SAFETY AND EFFICACY OF THE TER
Page 147 and 148: Cytogenetics and molecular diagnost
Page 149 and 150: 0385 CYTOPLASMIC MUTATED NUCLEOPHOS
Page 151: 0390 ELTROMBOPAG RAISES PLATELET CO
Page 155 and 156: The cases of RAS showed two peaks o
Page 157 and 158: is 85%. Seven out of the 25 relapse
Page 159 and 160: 0409 FRACTIONATED RADIOIMMUNOTHERAP
Page 161 and 162: 0414 COMPARATIVE ANALYSIS OF THE CO
Page 163 and 164: successfully managed with GM-CSF di
Page 165 and 166: 49% for PCR positive patients (95%
Page 167 and 168: +8 (1 PR+1 HI) and 14/24 pts with c
Page 169 and 170: (e.g. bcr-abl leading to CML). CSC
Page 171 and 172: 0438 TERC MUTATIONS ANALYSIS IN PAT
Page 173 and 174: observed in all mice. Analysis of l
Page 175 and 176: ex-vivo expansion of HUCB-derived H
Page 177 and 178: ic kidney disease in univariate or
Page 179 and 180: One hundred eleven CN AML patients,
Page 181 and 182: to asses intestinal epithelial dama
Page 183 and 184: genesis of acute myeloid leukaemia
Page 185 and 186: polymorphism at nucleotide 4889 of
Page 187 and 188: expression along with a decreased C
Page 189 and 190: 0487 MUTATIONAL STATUS OF NUCLEOPHO
Page 191 and 192: previously reported, a single cours
Page 193 and 194: 0497 SINGLE AGENT CLORETAZINE (VNP4
Page 195 and 196: ly received melphalan-based chemoth
Page 197 and 198: were similar among the 3 groups. Ho
Page 199 and 200: Methods. Several read-out systems w
Page 201 and 202: 0518 SERUM AND CELLULAR EXPRESSION
Page 203 and 204:
0523 DNA REPAIR INHIBITION IN RESTO
Page 205 and 206:
held true when BMI-1 expression was
Page 207 and 208:
Ph + cells in the bone marrow). We
Page 209 and 210:
derivative chromosome (4p16, 7p14,
Page 211 and 212:
0545 STABILIZED BONE MARROW IS NOT
Page 213 and 214:
obtained in low (Sokal) risk patien
Page 215 and 216:
median dose intensity being 800 (21
Page 217 and 218:
from pivotal clinical trials. Metho
Page 219 and 220:
Cytogenetics and Molecular diagnost
Page 221 and 222:
to set up and optimize a D-HPLC-bas
Page 223 and 224:
0576 WESTERN BLOT IDENTIFICATION OF
Page 225 and 226:
Basic disease was AML (n=5), ALL (n
Page 227 and 228:
0588 EXTRACORPOREAL PHOTOPHORESIS F
Page 229 and 230:
acquire a cytolytic capacity agains
Page 231 and 232:
informed vignettes describing healt
Page 233 and 234:
using CHOP-21 in the UK, pegfilgras
Page 235 and 236:
0609 SOFT TISSUE COMPLICATIONS IN P
Page 237 and 238:
inding lectin (MBL) gene by polymer
Page 239 and 240:
all infection rate (p=0.12) as well
Page 241 and 242:
Myelodysplastic syndromes II 0623 M
Page 243 and 244:
formation (in total 28 samples). Ti
Page 245 and 246:
sion. In addition, confocal analysi
Page 247 and 248:
Myeloproliferative disorders - Clin
Page 249 and 250:
open-label, multi-centre study enro
Page 251 and 252:
iopsies after 6 and 12 months treat
Page 253 and 254:
Myeloproliferative disorders Chroni
Page 255 and 256:
ash, muscolar cramps, diarrhoea, he
Page 257 and 258:
induced significant apoptosis (mean
Page 259 and 260:
Myeloma and other monoclonal gammop
Page 261 and 262:
the therapy of choice for POEMS is
Page 263 and 264:
er patient does not indicate such t
Page 265 and 266:
Myeloma and other monoclonal gammop
Page 267 and 268:
secutive patients with MM, referred
Page 269 and 270:
whether gene expression values may
Page 271 and 272:
0705 THE SHIFT OF TREATMENT FOR NAS
Page 273 and 274:
0710 CLINICO-PATHOLOGICAL FEATURES,
Page 275 and 276:
patients presented a stage IV disea
Page 277 and 278:
plete remission or recurrent diseas
Page 279 and 280:
known at NHL diagnosis, were includ
Page 281 and 282:
0731 THE IMPACT OF HIV ON NON-HODGK
Page 283 and 284:
patients had died of their underlyi
Page 285 and 286:
scripts and proteins most affected
Page 287 and 288:
modulated after 24 h (37 up- and 59
Page 289 and 290:
0753 A SUSTAINED REMISSION OF IDIOP
Page 291 and 292:
and treatment, has rarely been syst
Page 293 and 294:
uncontrolled massive bleeding affec
Page 295 and 296:
Results. A total of 396 patients we
Page 297 and 298:
C30 questionnaire, and the correspo
Page 299 and 300:
wave length of light of reflected r
Page 301 and 302:
0783 PREVALENCE OF MEMBRANE PROTEIN
Page 303 and 304:
erozygous mother has a more severe
Page 305 and 306:
0794 CARDIAC MANIFESTATIONS IN A BR
Page 307 and 308:
0799 INEFFECTIVE ERYTHROPOIESIS IN
Page 309 and 310:
p=0.014 and p=0.003, respectively).
Page 311 and 312:
0809 CURRENT APPROACH TO CHELATION
Page 313 and 314:
Thrombosis II 0814 UNSUSPECTED PULM
Page 315 and 316:
the 97.5th percentile (5.2 U/mL) ge
Page 317 and 318:
symptoms of DVT, 3 (7.89%) previous
Page 319 and 320:
Transfusion medicine and vascular b
Page 321 and 322:
tions (most bacterial, 2 malaria, 6
Page 323 and 324:
0844 INCREASED LEUKOCYTE-PLATELET I
Page 325 and 326:
0851 CORD BLOOD DERIVED MESENCHYMAL
Page 327 and 328:
SIMULTANEOUS SESSION II Chronic mye
Page 329 and 330:
0862 COMPARISON OF DASATINIB TO HIG
Page 331 and 332:
0867 COMPREHENSIVE GERIATRIC ASSESS
Page 333 and 334:
0872 MN1 INDUCES LEUKEMIA IN MICE A
Page 335 and 336:
0877 PAX5/TEL TRANSDUCED PRE-BI CEL
Page 337 and 338:
0882 CISPLATIN INDUCES THROMBIN GEN
Page 339 and 340:
have an early manifestation of typi
Page 341 and 342:
0892 INTEGRATION OF GENOME WIDE SNP
Page 343 and 344:
0897 THE PHENOTYPE OF JAK2V617F MUT
Page 345 and 346:
gest diverse sequences of NPM mutan
Page 347 and 348:
2004 to January, 2006. At enrollmen
Page 349 and 350:
with a p value of ≥ 0.10. Sets of
Page 351 and 352:
BRIC 126 and 4N1K) in cells lacking
Page 353 and 354:
sclerosis[NS] and 12 Mixed cellular
Page 355 and 356:
0927 MK-0457, A NOVEL MULTIKINASE I
Page 357 and 358:
Publication Only 0933 CLINICAL FEAT
Page 359 and 360:
HSCT from the available Asian as we
Page 361 and 362:
that the incidence of JAK2 mutation
Page 363 and 364:
without type 2 diabetes. Methods. T
Page 365 and 366:
pts (38.8%) that were isolated (abs
Page 367 and 368:
y using the Miltenyi CD34 isolation
Page 369 and 370:
0969 COMPARISON OF CD25 IMMUNOHISTO
Page 371 and 372:
cytes was 24 days (range 8-32 days)
Page 373 and 374:
a cytogenetic hallmark for M4/M5 su
Page 375 and 376:
normal human BM B progenitor cells
Page 377 and 378:
0994 INCIDENCE OF INVASIVE ASPERGIL
Page 379 and 380:
3 of disease relapse.TRM at day+100
Page 381 and 382:
survival of five years. This dismal
Page 383 and 384:
1011 FLOW CYTOMETRIC DNA INDEX AND
Page 385 and 386:
1018 THE EFFECT OF THE SUGARBAKER P
Page 387 and 388:
1024 KIR/HLA CLASS I MISMATCHING AN
Page 389 and 390:
ment details and thrombotic histori
Page 391 and 392:
1036 INCIDENCE AND SPECTRUM OF INFE
Page 393 and 394:
tinely by our stem cell lab prior t
Page 395 and 396:
tion to a translocation t(5;14)(q35
Page 397 and 398:
ment of CML and induces a high rate
Page 399 and 400:
due to reactivation and/or progress
Page 401 and 402:
1063 ABNORMAL METHYLATION STATUS OF
Page 403 and 404:
1069 CLINICAL RELEVANCE OF REGULATO
Page 405 and 406:
1076 SERUM LEVELS OF SOLUBLE HLA CL
Page 407 and 408:
patient is still undergoing intensi
Page 409 and 410:
nificant MVD differences were detec
Page 411 and 412:
dictor of OS (p=0.004). High dose t
Page 413 and 414:
1099 ALTERATIONS IN THE NATURAL KIL
Page 415 and 416:
1105 CYTOGENETIC ABNORMALITIES IN 3
Page 417 and 418:
1110 CONSTITUTIVE ACTIVATION OF STA
Page 419 and 420:
efficacy results with a well-tolera
Page 421 and 422:
unmutated VH genes, and high and lo
Page 423 and 424:
Aims. Aim of this study was to pred
Page 425 and 426:
tested across a wide range of human
Page 427 and 428:
were incidentally diagnosed (52%).
Page 429 and 430:
ß2GP1 may be considered as determi
Page 431 and 432:
characterized in 198 β thalassaemi
Page 433 and 434:
1155 PLATELET AGGREGATION IN CHILDR
Page 435 and 436:
to-pelvic or perineal trauma. No me
Page 437 and 438:
in age. High prevalence of LBM amon
Page 439 and 440:
ecause some of the patients were or
Page 441 and 442:
of the drug is crucial to allow lon
Page 443 and 444:
egarding cost analysis of ASCT in G
Page 445 and 446:
ID Allo-BMT, 1 family one mismatche
Page 447 and 448:
admitted to ICU were discharged des
Page 449 and 450:
events -Postoperative states: 9,19%
Page 451 and 452:
efficacy and decreased atherosclero
Page 453 and 454:
1217 INCIDENCE OF EARLY STAGE IDIOP
Page 455 and 456:
1691GA and 1 homozygous 1691AA. The
Page 457 and 458:
1230 ASSOCIATION OF HEPARANASE GENE
Page 459 and 460:
posed, was: DF = (CD43%+FMC7%+CD79b
Page 461 and 462:
treatment of acute promyelocityc le
Page 463 and 464:
loaded group and 35 (70%) were non-
Page 465 and 466:
mild. Fas and soluble Fas ligand le
Page 467 and 468:
1265 POSACONAZOLE THERAPY IN REFRAC
Page 469 and 470:
ly express the cytoplasmic (inactiv
Page 471 and 472:
findings confirmed the significant
Page 473 and 474:
a less favorable prognosis. Interes
Page 475 and 476:
disease (HD), 4 patients (9%) with
Page 477 and 478:
1295 HEMOPHAGOCYTIC LYMPHOHYSTIOCYT
Page 479 and 480:
phamide 750 mg/m 2 on day 1, vincri
Page 481 and 482:
nomenon is unclear. It has been sug
Page 483 and 484:
oped mild thrombocytopenia (platele
Page 485 and 486:
gle dose of 54mg/m 2 rituximab furt
Page 487 and 488:
patients (pts), 36 male, with acute
Page 489 and 490:
esulting alterations of the endothe
Page 491 and 492:
(range 1-7) and 28,6% of patients h
Page 493 and 494:
three decades. In vivo, Ara-C is tr
Page 495 and 496:
statistical analysis. Results. Seve
Page 497 and 498:
Results. Though there was no recogn
Page 499 and 500:
2% and 19% of patients with or with
Page 501 and 502:
were older than 65 y) which can be
Page 503 and 504:
1376 RESVERATROL INDUCED P53 MEDIAT
Page 505 and 506:
median time of 21 days to reach >0.
Page 507 and 508:
ly. Conclusions. 1. Combined intens
Page 509 and 510:
to the presence of IVS1-6 mutation
Page 511 and 512:
fy predictive factors for these abn
Page 513 and 514:
acute leukemia. However, we cannot
Page 515 and 516:
agents. They involve primarily the
Page 517 and 518:
voriconazole for 2 months followed
Page 519 and 520:
typed using a commercially availabl
Page 521 and 522:
low up of ABL KD mutations’ level
Page 523 and 524:
with development of BC/AP. 2. EVI-1
Page 525 and 526:
1447 THE IMPACT OF DISPARITY IN SHO
Page 527 and 528:
three had visual field defects, two
Page 529 and 530:
acquired mutation most prone to cau
Page 531 and 532:
1466 ROS GENERATION AND APOPTOSIS I
Page 533 and 534:
1473 DIARRHEIC SYNDROME, A CLINICAL
Page 535 and 536:
gene fusion is an independent progn
Page 537 and 538:
1484 EPIDEMIOLOGY AND RESPONSE TO T
Page 539 and 540:
1492 FREQUENCY OF MEDITERRANEAN GLU
Page 541 and 542:
immune globulin was administered at
Page 543 and 544:
maintained on Imatinib 400 mg. Afte
Page 545 and 546:
Hodgkin’s disease is well known,
Page 547 and 548:
gram provided a unique chance to de
Page 549 and 550:
even when ADP-induced plt activatio
Page 551 and 552:
medullary involvement of multiple m
Page 553 and 554:
1540 ADMINISTRATION OF G-CSF AND CH
Page 555 and 556:
1548 QUALITY ANALYSIS OF THE MULTID
Page 557 and 558:
Index of authors A Aapro, M., 0377,
Page 559 and 560:
Bahr, J., 0148 Bai, M., 1551 Baia,
Page 561 and 562:
Bottini, P.V., 1181 Botto, B., 0408
Page 563 and 564:
Chaidos, A., 0456, 0498, 0599, 0686
Page 565 and 566:
De Keersmaecker, K., 0442, 0875 De
Page 567 and 568:
El-Sharkawy, N., 0016 Elwahidi, G.,
Page 569 and 570:
Garcia-Frade, J., 0346, 0680, 1105
Page 571 and 572:
H Haas, N., 0742 Haas, O.A., 0001,
Page 573 and 574:
Jaksic, B., 0127, 0446 Jaksic, O.,
Page 575 and 576:
Körmöczi, G., 0848 Kornblau, S.,
Page 577 and 578:
Lin, L.-I., 0030, 0484 Lin, T., 012
Page 579 and 580:
Massé, A., 0249 Massó, P., 1287,
Page 581 and 582:
Musto, P., 0254, 0401, 0422, 0569,
Page 583 and 584:
Papadavid, E., 1442 Papageorgiou, E
Page 585 and 586:
Probatova, N., 0704 Prochazka, V.,
Page 587 and 588:
Rykavicin, O., 0504 Ryningen, A., 0
Page 589 and 590:
Sirard, C., 0127, 0128 Sirigou, A.,
Page 591 and 592:
Thiebaut, A., 0454 Thieblemont, C.,
Page 593 and 594:
Vincenzi, C., 1060 Viniou, N.-A., 0
Page 595 and 596:
Zouabi, H., 0503, 0999 Zoumbos, N.C
Page 597 and 598:
Page 599 and 600:
Page 601 and 602:
Page 603:
show all

12th Congress of the European Hematology ... - Haematologica

Create successful ePaper yourself

Delete template?

Save as template?